Outcomes and Treatment Patterns for Recurrence Following Concurrent Chemoradiation and Consolidation Durvalumab in Locally Advanced, Unresectable NSCLC: A Multi-Center Study
Clinical Lung Cancer · 2026-11
DOI: 10.1016/j.cllc.2026.11.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lung Cancer, 2026-11. Verfasst von Richard D. Hall und 23 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Introduction
The PACIFIC trial demonstrated significant overall survival improvement with the addition of consolidation durvalumab after concurrent chemotherapy and radiation for patients with unresectable stage III NSCLC. Despite this advance, the majority of patients do not survive five years. Post-progression outcomes are not well known for patients who have received durvalumab treatment for stage III NSCLC.
Methods
Patients with NSCLC who received definitive concurrent chemotherapy and radiation followed by ≥1 dose of durvalumab without EGFR or ALK alterations were identified retrospectively. The primary outcomes of the study were progression-free survival 2 (PFS2) and overall survival 2 (OS2) from the time of post-durvalumab progression.
Results
190 patients who received durvalumab consolidation between January 2018 and July 2022 were included. For 91 patients with a progression event after ≥ 1 dose of durvalumab, median PFS2 was 7.9 months and median OS2 was 12.1 months. For those with distant recurrence, the most common sites of distant metastases were CNS, bone, and liver. There were no statistically significant differences in PFS2 or OS2 based on timing of recurrence (≤1 year vs. >1 year) or location of recurrence (local vs. distant).
Conclusion
Post-progression outcomes are poor for patients with recurrence after treatment with consolidation durvalumab for patients with stage III unresectable NSCLC with median PFS2 of only 7.9 months and median OS2 of only 12.1 months. There are no significant differences in post-recurrence outcomes for those with local only recurrence or recurrence more than one year after starting durvalumab consolidation.
Zitieren
APA
Hall, R. D., Young, P., Sharp, J., Michaels, K., Fultineer, K., Larner, J. M., Thomas, M. C., Lynch, A. C., Chen, M., Zhu, H., Li, M., Roof, L., He, K., Shields, P., Kaufman, J., Memmott, R., Alahmadi, A., Carbone, D. P., Otterson, G. A., …, & Gentzler, R. D. (2026). Outcomes and Treatment Patterns for Recurrence Following Concurrent Chemoradiation and Consolidation Durvalumab in Locally Advanced, Unresectable NSCLC: A Multi-Center Study. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2026.11.006
Vancouver
Hall RD, Young P, Sharp J, Michaels K, Fultineer K, Larner JM, et al. Outcomes and Treatment Patterns for Recurrence Following Concurrent Chemoradiation and Consolidation Durvalumab in Locally Advanced, Unresectable NSCLC: A Multi-Center Study. Clinical Lung Cancer. 2026. doi:10.1016/j.cllc.2026.11.006
BibTeX
@article{Hall2026,
author = {Hall, Richard D. and Young, Philip and Sharp, John and Michaels, Kenan and Fultineer, Kylie and Larner, James M. and Thomas, Marie C. and Lynch, Alia C. and Chen, Mu-Hsun and Zhu, Hong and Li, Mingjia and Roof, Logan and He, Kai and Shields, Peter and Kaufman, Jacob and Memmott, Regan and Alahmadi, Asrar and Carbone, David P. and Otterson, Gregory A. and Presley, Carolyn J. and Haglund, Karl and Brownstein, Jeremy and Owen, Dwight H. and Gentzler, Ryan D.},
title = {Outcomes and Treatment Patterns for Recurrence Following Concurrent Chemoradiation and Consolidation Durvalumab in Locally Advanced, Unresectable NSCLC: A Multi-Center Study},
journal = {Clinical Lung Cancer},
year = {2026},
doi = {10.1016/j.cllc.2026.11.006}
}
EUVIMED